MedTrace Logo

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

NCT05263921 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants. The study will also assess the effect of 3 different food vehicles on the relative bioavailability of the PF-07321332/ritonavir oral powder formulation as well as the safety, tolerability, and palatability of PF-07321332/ritonavir oral powder in healthy adult participants.

Conditions

  • Bioavailability

Interventions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir under fasted conditions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions

DRUG

PF-07321332/ritonavir

Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2022-05-19
Completion
2022-05-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05263921 on ClinicalTrials.gov